Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice | springermedicine.com

Springer Medicine

Top

Published in:

Open Access 01-12-2008 | Research article

Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice

Authors: Johanna M Tuomela, Maija P Valta, Kalervo Väänänen, Pirkko L Härkönen

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Metastatic prostate cancer is associated with a high morbidity and mortality but the spreading mechanisms are still poorly understood. The aminobisphosphonate alendronate, used to reduce bone loss, has also been shown to inhibit the invasion and migration of prostate cancer cells in vitro. We used a modified orthotopic PC-3 nude mouse tumor model of human prostate cancer to study whether alendronate affects prostate tumor growth and metastasis.

Methods

PC-3 cells (5 × 10⁵) were implanted in the prostates of nude mice and the mice were treated with alendronate (0.5 mg/kg/day in PBS, s.c.) or vehicle for 4 weeks. After sacrifice, the sizes of tumor-bearing prostates were measured and the tumors and prostate-draining regional iliac and sacral lymph nodes were excised for studies on markers of proliferation, apoptosis, angiogenesis and lymphangiogenesis, using histomorphometry and immunohistochemistry.

Results

Tumor occurrence in the prostate was 73% in the alendronate-treated group and 81% in the control group. Mean tumor size (218 mm³, range: 96–485 mm³, n = 11) in the alendronate-treated mice was 41% of that in the control mice (513 mm³, range: 209–1350 mm³, n = 13) (p < 0.05). In the iliac and sacral lymph nodes of alendronate-treated mice, the proportion of metastatic area was only about 10% of that in control mice (p < 0.001). Immunohistochemical staining of tumor sections showed that alendronate treatment caused a marked decrease in the number of CD34-positive endothelial cells in tumors (p < 0.001) and an increase in that of ISEL positive apoptotic cells in tumors as well as in lymph node metastases (p < 0.05) compared with those in the vehicle-treated mice. The density of m-LYVE-1-stained lymphatic capillaries was not changed.

Conclusion

Our results demonstrate that alendronate treatment opposes growth of orthotopic PC-3 tumors and decreases tumor metastasis to prostate-draining lymph nodes. This effect could be at least partly explained by decreased angiogenesis and increased apoptosis. The results suggest that bisphosphonates have anti-tumoral and anti-invasive effects on primary prostate cancer.

Available only for authorised users

1.

Gronberg H: Prostate cancer epidemiology. Lancet. 2003, 361 (9360): 859-864. 10.1016/S0140-6736(03)12713-4.CrossRefPubMed

2.

Rassweiler J, Schulze M, Teber D, Marrero R, Seemann O, Rumpelt J, Frede T: Laparoscopic radical prostatectomy with the Heilbronn technique: oncological results in the first 500 patients. J Urol. 2005, 173 (3): 761-764. 10.1097/01.ju.0000153486.94741.e5.CrossRefPubMed

3.

Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006, 12 (20 Pt 2): 6243s-6249s. 10.1158/1078-0432.CCR-06-0931.CrossRefPubMed

4.

Roy-Burman P, Wu H, Powell WC, Hagenkord J, Cohen MB: Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer. 2004, 11 (2): 225-254. 10.1677/erc.0.0110225.CrossRefPubMed

5.

Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler IJ: Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst. 1992, 84 (12): 951-957. 10.1093/jnci/84.12.951.CrossRefPubMed

6.

Shevrin DH, Gorny KI, Kukreja SC: Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice. Prostate. 1989, 15 (2): 187-194. 10.1002/pros.2990150212.CrossRefPubMed

7.

Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, Chung LW: Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer. 1998, 77 (6): 887-894. 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z.CrossRefPubMed

8.

Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996, 19 (6): 663-667. 10.1016/S8756-3282(96)00285-2.CrossRefPubMed

9.

McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT: Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol. 2001, 113 (4): 1035-1043. 10.1046/j.1365-2141.2001.02851.x.CrossRefPubMed

10.

Guise TA: Bone loss and fracture risk associated with cancer therapy. Oncologist. 2006, 11 (10): 1121-1131. 10.1634/theoncologist.11-10-1121.CrossRefPubMed

11.

Reginster JY, Sarlet N: The treatment of severe postmenopausal osteoporosis: a review of current and emerging therapeutic options. Treat Endocrinol. 2006, 5 (1): 15-23. 10.2165/00024677-200605010-00003.CrossRefPubMed

12.

Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT: Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res. 2002, 62 (9): 2708-2714.PubMed

13.

van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996, 98 (3): 698-705. 10.1172/JCI118841.CrossRefPubMedPubMedCentral

14.

Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997, 57 (18): 3890-3894.PubMed

15.

Stearns ME, Wang M: Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis. 1998, 16 (8): 693-702. 10.1023/A:1006524610591.CrossRefPubMed

16.

Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001, 84 (8): 1126-1134. 10.1054/bjoc.2001.1727.CrossRefPubMedPubMedCentral

17.

Fromigue O, Lagneaux L, Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000, 15 (11): 2211-2221. 10.1359/jbmr.2000.15.11.2211.CrossRefPubMed

18.

Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P: Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002, 62 (22): 6538-6544.PubMed

19.

Wakchoure S, Merrell MA, Aldrich W, Millender-Swain T, Harris KW, Triozzi P, Selander KS: Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res. 2006, 12 (9): 2862-2868. 10.1158/1078-0432.CCR-05-2766.CrossRefPubMed

20.

Padalecki SS, Guise TA: Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Res. 2002, 4 (1): 35-41. 10.1186/bcr415.CrossRefPubMed

21.

Hiraga T, Williams PJ, Mundy GR, Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 2001, 61 (11): 4418-4424.PubMed

22.

Hashimoto K, Morishige K, Sawada K, Tahara M, Kawagishi R, Ikebuchi Y, Sakata M, Tasaka K, Murata Y: Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res. 2005, 65 (2): 540-545.PubMed

23.

Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T: Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004, 10 (13): 4559-4567. 10.1158/1078-0432.CCR-03-0325.CrossRefPubMed

24.

Yamagishi S, Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, Nakamura H, Shimizu T, Takeuchi M, Yoshimura A, Bucala R, Shimizu H, Imaizumi T: Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol. 2004, 165 (6): 1865-1874.CrossRefPubMedPubMedCentral

25.

Giraudo E, Inoue M, Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004, 114 (5): 623-633.CrossRefPubMedPubMedCentral

26.

Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F: Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer. 2005, 104 (11): 2522-2529. 10.1002/cncr.21530.CrossRefPubMed

27.

Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002, 302 (3): 1055-1061. 10.1124/jpet.102.035295.CrossRefPubMed

28.

Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J, Pylkkanen L: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002, 20 (15): 3219-3224. 10.1200/JCO.2002.11.080.CrossRefPubMed

29.

Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998, 339 (6): 357-363. 10.1056/NEJM199808063390601.CrossRefPubMed

30.

Saarto T, Blomqvist C, Virkkunen P, Elomaa I: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001, 19 (1): 10-17.PubMed

31.

Janik P, Briand P, Hartmann NR: The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res. 1975, 35 (12): 3698-3704.PubMed

32.

Jackson DG, Prevo R, Clasper S, Banerji S: LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol. 2001, 22 (6): 317-321. 10.1016/S1471-4906(01)01936-6.CrossRefPubMed

33.

Ruohola JK, Viitanen TP, Valve EM, Seppanen JA, Loponen NT, Keskitalo JJ, Lakkakorpi PT, Harkonen PL: Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res. 2001, 61 (10): 4229-4237.PubMed

34.

Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162 (1): 156-159. 10.1016/0003-2697(87)90021-2.CrossRefPubMed

35.

Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo J. 1996, 15 (7): 1751-PubMedPubMedCentral

36.

Berquin IM, Min Y, Wu R, Wu H, Chen YQ: Expression signature of the mouse prostate. J Biol Chem. 2005, 280 (43): 36442-36451. 10.1074/jbc.M504945200.CrossRefPubMed

37.

Li J, Wang E, Rinaldo F, Datta K: Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway. Oncogene. 2005, 24 (35): 5510-5520. 10.1038/sj.onc.1208693.CrossRefPubMed

38.

Wong SY, Haack H, Crowley D, Barry M, Bronson RT, Hynes RO: Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res. 2005, 65 (21): 9789-9798. 10.1158/0008-5472.CAN-05-0901.CrossRefPubMed

39.

Bader P, Burkhard FC, Markwalder R, Studer UE: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?. J Urol. 2003, 169 (3): 849-854. 10.1097/01.ju.0000049032.38743.c7.CrossRefPubMed

40.

Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW: Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol. 2003, 170 (1): 246-252. 10.1097/01.ju.0000070685.34760.5f.CrossRefPubMed

41.

Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004, 96 (11): 879-882.CrossRefPubMed

42.

Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002, 94 (19): 1458-1468.CrossRefPubMed

43.

Parker CC: Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004, 96 (19): 1480-1481.CrossRefPubMed

44.

Parker CC: The role of bisphosphonates in the treatment of prostate cancer. BJU Int. 2005, 95 (7): 935-938. 10.1111/j.1464-410X.2005.05441.x.CrossRefPubMed

45.

Stearns ME, Wang M: Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis. 1996, 16 (3): 116-131.PubMed

46.

Suri S, Monkkonen J, Taskinen M, Pesonen J, Blank MA, Phipps RJ, Rogers MJ: Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone. 2001, 29 (4): 336-343. 10.1016/S8756-3282(01)00589-0.CrossRefPubMed

47.

Muller S, Migianu E, Lecouvey M, Kraemer M, Oudar O: Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro. Anticancer Res. 2005, 25 (4): 2655-2660.PubMed

48.

Zhou Z, Guan H, Duan X, Kleinerman ES: Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer. 2005, 104 (8): 1713-1720. 10.1002/cncr.21383.CrossRefPubMed

49.

Salven P, Lymboussaki A, Heikkila P, Jaaskela-Saari H, Enholm B, Aase K, von Euler G, Eriksson U, Alitalo K, Joensuu H: Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol. 1998, 153 (1): 103-108.CrossRefPubMedPubMedCentral

50.

Stearns ME: Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clin Exp Metastasis. 1998, 16 (4): 332-339. 10.1023/A:1006513413583.CrossRefPubMed

51.

Achen MG, McColl BK, Stacker SA: Focus on lymphangiogenesis in tumor metastasis. Cancer Cell. 2005, 7 (2): 121-127. 10.1016/j.ccr.2005.01.017.CrossRefPubMed

52.

Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K: Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001, 61 (5): 1786-1790.PubMed

53.

Tsurusaki T, Kanda S, Sakai H, Kanetake H, Saito Y, Alitalo K, Koji T: Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer. 1999, 80 (1–2): 309-313. 10.1038/sj.bjc.6690356.CrossRefPubMedPubMedCentral

54.

Mattila MM, Ruohola JK, Karpanen T, Jackson DG, Alitalo K, Harkonen PL: VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer. 2002, 98 (6): 946-951. 10.1002/ijc.10283.CrossRefPubMed

55.

Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001, 7 (2): 192-198. 10.1038/84643.CrossRefPubMed

56.

Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature. 2000, 407 (6801): 249-257. 10.1038/35025220.CrossRefPubMed

57.

Kimbro KS, Simons JW: Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer. 2006, 13 (3): 739-749. 10.1677/erc.1.00728.CrossRefPubMed

58.

Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A: Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer. 2006, 13 (1): 7-26. 10.1677/erc.1.01094.CrossRefPubMed

59.

Monkkonen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsalainen J, Monkkonen J: A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol. 2006, 147 (4): 437-445. 10.1038/sj.bjp.0706628.CrossRefPubMedPubMedCentral

60.

Oades GM, Coxon J, Colston KW: The potential role of bisphosphonates in prostate cancer. Prostate Cancer Prostatic Dis. 2002, 5 (4): 264-272. 10.1038/sj.pcan.4500607.CrossRefPubMed

61.

Merrell MA, Wakchoure S, Lehenkari PP, Harris KW, Selander KS: Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. Eur J Pharmacol. 2007

62.

Frith JC, Rogers MJ: Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res. 2003, 18 (2): 204-212. 10.1359/jbmr.2003.18.2.204.CrossRefPubMed

63.

Kaida H, Ishibashi M, Baba K, Nishida H, Matsuoka K, Hayabuchi N: Extraosseous uptake of metastatic lymph nodes of ureteral cancer on 99Tcm hydroxymethylene diphosphonate bone scintigraphy. Br J Radiol. 2004, 77 (922): 869-870. 10.1259/bjr/14405146.CrossRefPubMed

64.

Shih WJ, DeLand FH, Domstad PA, Johnston EH: Extraosseous localization of 99mTc-MDP in ganglioneuroblastoma. Eur J Nucl Med. 1982, 7 (7): 336-338. 10.1007/BF00253434.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/8/81/prepub

Title: Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice
Authors: Johanna M Tuomela
Maija P Valta
Kalervo Väänänen
Pirkko L Härkönen
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-8-81

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties